Patents Assigned to Sumitomo Pharmaceuticals Company Ltd.
-
Patent number: 6613799Abstract: New derivatives of platinum (II) complex are herein provided, which are liposoluble and applicable as antimicrobial agents and anticancer agents specific to the affected parts of patients and selectively transferred to the parts if they are used in combination with a contrast medium such as lipiodol, the derivatives being represented by the following general formula: (wherein R1 and R2 may be identical or different with each other and represent an ammine optionally substituted with an organic substituent and they may be bonded together through a bivalent organic group and R3 is a saturated or unsaturated higher fatty acid, these derivatives being prepared by nitrifying a cis-dichloro-di-(substituted or unsubstituted)-ammine platinum (II) and then reacting the resulting aqua type product with a corresponding alkali metal salt of higher fatty acid.Type: GrantFiled: March 5, 1986Date of Patent: September 2, 2003Assignee: Sumitomo Pharmaceuticals Company Ltd.Inventors: Mitsuaki Maeda, Takuma Sasaki
-
Patent number: 5843957Abstract: Naphthyridine derivative of the formula: ##STR1## wherein Ring A is substituted or unsubstituted pyridine, X is --N(R.sup.2)--CO--(R.sup.2 is H, alkyl, substituted alkyl, etc.), Z is a direct bond, --NH--, C.sub.1 -C.sub.2 alkylene, or --CH.dbd.CH--, Y is alkyl, substituted alkyl, aromatic group or substituted aromatic group, etc., B is alkyl, substituted alkyl, aromatic group or substituted aromatic group, or an acid addition salt thereof, these compounds having acyl-CoA: cholesterol acyl transferase inhibitory activity, and being useful as an agent for prophylaxis or treatment of hyperlipidemia, atherosclerosis, and related diseases thereof.Type: GrantFiled: November 25, 1997Date of Patent: December 1, 1998Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Masami Muraoka, Katsuhisa Ioriya, Naohito Ohashi, Hideki Yagi
-
Patent number: 5817492Abstract: An animal cell is co-transfected with both a recombinant DNA viral vector which bears a promoter, a recombinase gene and a poly(A) sequence and a recombinant DNA viral vector which bears two recombinase-recognizing sequences and which further bears an origin of replication, a promoter, a foreign gene and a poly(A) sequence, each of which is located between the two recombinase-recognizing sequences. Thereafter, in the co-transfected animal cell, a DNA fragment containing the origin of replication, promoter, foreign gene and poly(A) sequence is excised from the vector by the action of a recombinase expressed in the another vector. The DNA fragment forms a circular DNA molecule which autonomously replicates in the co-transfected animal cell due to the origin of replication, whereby the foreign gene is continuously expressed.Type: GrantFiled: August 30, 1995Date of Patent: October 6, 1998Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Izumu Saito, Yumi Kanegae
-
Patent number: 5766864Abstract: A method of measuring the activity of interferon-.alpha., .beta. or .omega., which comprises bringing a sample containing interferon into contact with a cell and determining an induced protein is provided.Type: GrantFiled: November 1, 1995Date of Patent: June 16, 1998Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Kazuko Uno, Tsunataro Kishida, Keiji Fujioka, Yoshihiro Takada, Takayuki Sato
-
Patent number: 5731172Abstract: Disclosed are a recombinant adenovirus bearing a DNA sequence encoding a desired foreign polypeptide, and a hybrid promoter (CAG promoter) comprising a cytomegalovirus enhancer, a chicken .beta.-actin promoter, a rabbit .beta.-globin splicing acceptor and a polyA sequence, a process for production thereof, as well as use thereof for in genetic treatment. The recombinant adenovirus effectively expresses the foreign polypeptide in a wide range of animal cells.Type: GrantFiled: September 8, 1994Date of Patent: March 24, 1998Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Izumu Saito, Yumi Kanegae
-
Patent number: 5698232Abstract: An interferon is administered singly or in combination with other pharmacological agents to patients with idiopathic sudden sensorineural hearing loss, whereby the patients are remarkably improved.Type: GrantFiled: November 8, 1996Date of Patent: December 16, 1997Assignees: Sumitomo Pharmaceuticals Company, Ltd., Hoffmann-La Roche Inc., Takeda Chemical Industries, Ltd.Inventors: Shinichi Kanemaru, Hideyuki Fukushima
-
Patent number: 5532372Abstract: An imide compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which the substituents are defined herein, and n is an integer of 0 to 1;D is a group of the formula:--(CH.sub.2).sub.p --A--(CH.sub.2).sub.q --in which A is a non-aromatic hydrocarbon ring optionally bridged with a lower alkylene group or an oxygen atom, said non-aromatic hydrocarbon ring and said lower alkylene group being each optionally substituted with at least one lower alkyl, and p and q are each an integer of 0, 1 or 2; andAr is an aromatic group, a heterocyclic aromatic group, a benzoyl group, a phenoxy group or a phenylthio group and G is >N--, >CH-- or >COH-- or Ar is a biphenylmethylidene group and G is >C.dbd., all of the above groups being each optionally substituted with at least one of lower alkyl, lower alkoxy and halogen; and its acid addition salts, useful as an antipsycotic agent.Type: GrantFiled: August 30, 1993Date of Patent: July 2, 1996Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Ikutaro Saji, Masayuki Muto, Norihiko Tanno, Mayumi Yoshigi
-
Patent number: 5385738Abstract: The present invention relates to a sustained-release injection, which comprises a suspension of a powder comprising an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, polysaccharides and synthetic high molecular compounds, preferably collagen, atelocollagen, gelatin, and a mixture thereof) in a viscous solvent for injection (e.g. vegetable oils, polyethylene glycol, propylene glycol, silicone oil, and medium-chain fatty acid triglycerides). The sustained-release injection can release the active ingredient at an effective level for a long period of time when injected.Type: GrantFiled: March 4, 1992Date of Patent: January 31, 1995Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Yoshiya Yamahira, Keiji Fujioka, Shigeji Sato, Yoshihiro Takada
-
Patent number: 5278297Abstract: A gene coding for Protein H, which is capable of binding specifically to human IgG of all subclasses, was isolated from Streptococcus sp. AP1 and expressed in host cells, E. coli to produce the Protein H.Type: GrantFiled: October 15, 1992Date of Patent: January 11, 1994Assignees: Sumitomo Pharmaceuticals Company, Ltd., HighTech Receptor ABInventors: Hideyuki Gomi, Tatsunobu Hozumi, Shizuo Hattori, Chiaki Tagawa, Fumitaka Kishimoto, Lars Bjorck
-
Patent number: 5081156Abstract: A sustained-release preparation of indomethacin or interferon comprising the active ingredient in admixture with a pharmaceutically acceptable biodegradable carrier, particularly a carrier selected from collagen, gelatin, and a mixture thereof. Said preparation is particularly suitable for parenteral administration and can release the active ingredient in an effective amount for a long period of time.Type: GrantFiled: May 30, 1989Date of Patent: January 14, 1992Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Yoshiya Yamahira, Keiji Fujioka, Shigeji Sato
-
Patent number: 4880832Abstract: New delivatives of platinum (IT) complex which are liposoluble and applicable as antibacterial agents or anticancer agents specific to the affected parts of patients and selectively transferred to the parts when they are used in combination with lipidol, the delivatives being represented by the general formula of: ##STR1## (wherein R.sub.1 and R.sub.2 each stands for a ligand ammine which may have an organic substituent or may be bonded to each other through a bivalent organic group and R.sub.3 represents a bile acid residue). These delivatives being prepared by nitrifying a cis-dichloro-di-(substituted or unsubstituted)-ammine platinum (II) and then reacting the resulting aqua type product with a corresponding alkali metal salt of bile acid.Type: GrantFiled: February 18, 1988Date of Patent: November 14, 1989Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Mitsuaki Maeda, Takuma Sasaki
-
Patent number: 4880827Abstract: Pyrrolidine derivatives having inhibitory action for proline-specific endopeptidase which are useful for anti-amnestic agent. The disclosed pyrrolidine derivatives as well as their acid addition salts can be administered orally or parenterally in the form of conventional pharmaceutical preparations. For instance, they can be administered orally in the form of conventional solid pharmaceutical preparations such as tablets, capsules, syrups and suspensions. Alternatively, they can be administered parenterally by injection in the form of conventional liquid pharmaceutical preparations such as solutions, emulsions, suspensions, etc. Also, they may be directly applied to rectum in the form of suppository. Further, the preparations may contain physiologically acceptable carriers, excipients, activators, binding agents, stabilizers, etc. In the case of injections, physiologically acceptable buffers, solubilizing agents or isotonic agents may be incorporated therein. Methods of production are also disclosed.Type: GrantFiled: March 13, 1987Date of Patent: November 14, 1989Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Katsumi Tamoto, Renzo Ohuchi, Keiichi Ono
-
Patent number: 4774091Abstract: A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained-release preparation can be administered to the body or implanted into the body by injection or an injection-like method and can release the active ingredient at an effective level for a long period of time when administered.Type: GrantFiled: March 31, 1986Date of Patent: September 27, 1988Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Yoshiya Yamahira, Keiji Fujioka, Shiegeji Sato, Yoshihiro Takada
-
Patent number: 4695580Abstract: Novel phenylserine derivatives of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions, and a process for preparing the compounds are disclosed. The phenylserine derivatives and pharmaceutically acceptable acid addition salts are capable of inhibiting the biosynthesis of leucotrienes and/or antagonistic activity against SRS-A and hence are useful for prophylaxis and treatment of various allergic diseases (e.g. bronchial asthma, allergic nasitis, urticaria), ischemic heart diseases, ischemic encephalopathy, inflammation, or the like.Type: GrantFiled: December 19, 1984Date of Patent: September 22, 1987Assignee: Sumitomo Pharmaceuticals Company, Ltd.Inventors: Naohito Ohashi, Shoji Nagata, Masashi Nakatsuka, Kikuo Ishizumi, Junki Katsube, Shunji Aono, Teruo Sakurama